GNL Gut and Liver
  1. Jun-Hyung Cho, So-Young Jin, Suyeon Park. Comparison of tegoprazan and proton pump inhibitors for first-line Helicobacter pylori eradication: a systematic review with meta-analysis . Expert Review of Anti-infective Therapy 2025:1
    https://doi.org/10.1080/14787210.2025.2459722
  2. Jun-Hyung Cho. Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line Helicobacter pylori eradication: a real-world evidence study . Expert Review of Anti-infective Therapy 2024;22:793
    https://doi.org/10.1080/14787210.2024.2329251
  3. Joseph Edwin Kanu, Jonathan Soldera. Treatment of Helicobacter pylori with potassium competitive acid blockers: A systematic review and meta-analysis. World J Gastroenterol 2024;30:1213
    https://doi.org/10.3748/wjg.v30.i9.1213
  4. Jin Hee Noh. Current Status and Future Perspectives of Tegoprazan-Based Helicobacter pylori Eradication Therapy. Korean J Helicobacter Up Gastrointest Res 2024;24:100
    https://doi.org/10.7704/kjhugr.2024.0023
  5. Jun-Hyung Cho, So-Young Jin. Comparison of Amoxicillin Administered Twice versus Four Times a Day in First-Line Helicobacter pylori Eradication Using Tegoprazan, Clarithromycin, and Bismuth: A Propensity Score Matching Analysis. Microorganisms 2024;12:1952
    https://doi.org/10.3390/microorganisms12101952
  6. Qingzhou Kong, Iqtida Ahmed Mirza, Xiaoqian Zhang, Xiaohui Song, Xiaowei Li, Qiumei Zhang, Lidong Xu, Yuting Guo, Yanan Yu, Xiuli Zuo, Yanqing Li, Yueyue Li. Fourteen‐Day Tegoprazan–Amoxicillin Dual Therapy as the First‐Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial. Helicobacter 2024;29
    https://doi.org/10.1111/hel.13098
  7. Amit Patel, Loren Laine, Paul Moayyedi, Justin Wu. AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review. Gastroenterology 2024;167:1228
    https://doi.org/10.1053/j.gastro.2024.06.038
  8. Chan Hyuk Park. Helicobacter Infection in Clinical Practice. 2024.
    https://doi.org/10.1007/978-981-97-8397-7_15
  9. Yujing Du, Lixiu Yu, Bin Deng, Qinying Li, Junrui Hu, Linjie Li, Yusen Xu, Liangwei Song, Fang Xie, Yinghui Wang, Yuhao Chen, Chengxin Liu, Xuejia Zhai, Yongning Lu. Pharmacokinetic Interactions Between Tegoprazan and the Combination of Clarithromycin, Amoxicillin and Bismuth in Healthy Chinese Subjects: An Open-Label, Single-Center, Multiple-Dosage, Self-Controlled, Phase I Trial. Clin Drug Investig 2024;44:343
    https://doi.org/10.1007/s40261-024-01359-x
  10. Yujiao Wang, Xiaosong Dai, Xinxing Zhang. Network Meta-Analysis of Comparing Different Dosages of Potassium-Competitive Acid Blocker With Proton-Pump Inhibitor in Acid-Related Disorders. Clin Transl Gastroenterol 2024;15:e00776
    https://doi.org/10.14309/ctg.0000000000000776
  11. Seokin Kang, Nam-Hoon Kim, Seokhyeon Jeong, Jong Wook Kim, Jung Rock Moon, Yoon Suk Lee, Jun Hyuk Son. Comparison of Tegoprazan- and Lansoprazole-Based Fourteen-Day Triple Therapies as First-Line Treatments for Helicobacter pylori Eradication. Korean J Helicobacter Up Gastrointest Res 2024;24:168
    https://doi.org/10.7704/kjhugr.2024.0012
  12. Byung Wook Jung, Chan Hyuk Park, Yoon Suk Jung. Efficacy and safety of tegoprazan‐ and rabeprazole‐based concomitant therapies for Helicobacter pylori infection: Real‐world evidence. J of Gastro and Hepatol 2024;39:2409
    https://doi.org/10.1111/jgh.16719
  13. Byung Wook Jung, Yun Jin Kim, Chan Hyuk Park. Nationwide Trends in Helicobacter pylori Eradication Therapies in Korea: Impact of Guideline Updates on Treatment Practices. Helicobacter 2024;29
    https://doi.org/10.1111/hel.13152
  14. Chan Hyuk Park, Myung Jin Song, Byung Wook Jung, Jung Ho Park, Yoon Suk Jung. Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication. JPM 2022;12:1918
    https://doi.org/10.3390/jpm12111918
  15. Amit Patel, Loren Laine, Paul Moayyedi. Reply. Gastroenterology 2025
    https://doi.org/10.1053/j.gastro.2025.01.001
  16. Hyun Ho Choi. Is Tegoprazan-Based Triple Therapy Effective in Regions with High Rates of Clarithromycin Resistance?. Gut and Liver 2023;17:668
    https://doi.org/10.5009/gnl230338
  17. Carmelo Scarpignato, Richard H. Hunt. Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments. Curr Gastroenterol Rep 2024;26:273
    https://doi.org/10.1007/s11894-024-00939-3
© 2023. Gut and Liver. / Powered by INFOrang Co., Ltd